SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an oral presentation and two poster presentations relating to the company’s drug development candidates. These presentations will be made at the upcoming ENDO 2018, the Annual Meeting of the Endocrine Society, taking place from March 17-20, 2018 in McCormick Place West, Chicago, Illinois.

Oral Presentation:

Title: Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist for the Treatment of Acromegaly: Safety, Pharmacokinetics, and Inhibition of GHRH-Induced GH Secretion.
Session: OR06 - Pituitary Tumors: Acromegaly and Prolactinomas.
Poster: ORO6-3.
Date and Time: Saturday, March 17, 12-12:15 p.m. CDT
Location: W192.

Poster Presentations:

Title: Suppression of Growth Hormone and Insulin-Like Growth Factor 1 in Rats After Oral Administration of CRN00808, a Small Molecule, SST2 Selective Somatostatin Biased Agonist.
Session: P32 - Pituitary Transcription Factors and New Hormonal Signaling Pathways.
Poster: SUN-604.
Date and Time: Sunday, March 18, 1-3 p.m. CDT
Location: ENDOExpo, Hall F.

Title: Somatostatin Subtype 5 (sst5) Agonists for the Treatment of Hyperinsulinism: Orally-Bioavailable Small Molecules Suppress Insulin and Rescue Glyburide-Induced Hypoglycemia.
Session: P14-3 - Pediatric Endocrinology - Disorders of Sexual Differentiation, Transgender Medicine, Metabolic Disorders, and Growth.
Poster: MON-193.
Date and Time: Monday, March 19th, 1-3 p.m. CDT
Location: ENDOExpo, Hall F.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical-stage biotechnology company focusing on treatments for rare endocrine disorders and endocrine-related cancers. The company is currently conducting a Phase 1 trial with its oral nonpeptide somatostatin agonist, CRN00808, for the treatment of acromegaly, an orphan disease affecting more than 24,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for hyperinsulinism and neuroendocrine tumors, as well as an oral small molecule for Cushing's disease. Crinetics was founded by a team of scientists with a proven track record of endocrine drug discovery and development. The company is backed by top life sciences investors and is headquartered in San Diego. For additional information please visit www.crinetics.com

Contacts:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464

Robert H. Uhl
Westwicke Partners
robert.uhl@westwicke.com
(858) 356-5932